Based on hydrophilic and lipophilic properties of adjuvants, they are often used in vaccine delivery systems. They can reduce the toxicity of vaccines and increase immune activity. CD Bioparticles' services with customized delivery strategies, precise designs and modifications of drugs or drug-contained cargos, and advanced technical platforms can help you to solve:
Product Name | Catalog | Form | Unit Size | Price |
---|---|---|---|---|
22:0 Trehalose | CDLP-A01 | Powder | 5 mg | INQUIRY |
3A-MPLA | CDLP-A421 | Powder | 1 mg | INQUIRY |
3D-(6-acyl) PHAD® | CDLP-A419 | Powder | 1 mg | INQUIRY |
3D-PHAD® | CDLP-A418 | Powder | 1 mg | INQUIRY |
4A-MPLA | CDLP-A02 | Powder | 1 mg | INQUIRY |
ATP.3Na | CDSNT79 | 1 mL, 2 mL, 5 mL | INQUIRY | |
Cap AG | CDSNT74 | 1 mL, 2 mL, 5 mL | INQUIRY | |
CTP.3Na | CDSNT78 | 1 mL, 2 mL, 5 mL | INQUIRY | |
Dnase Ⅰ | CDSNT70 | 1 mL, 2 mL, 5 mL | INQUIRY | |
GTP.3Na | CDSNT77 | 1 mL, 2 mL, 5 mL | INQUIRY | |
MPLA (PHAD®) | CDLP-A422 | Powder | 1 mg | INQUIRY |
Murine RNase Inhibitor | CDSNT72 | 1 mL, 2 mL, 5 mL | INQUIRY | |
N1-Me-Pseudo-UTP | CDSNT75 | 1 mL, 2 mL, 5 mL | INQUIRY | |
PHAD®-504 | CDLP-A420 | Powder | 5 mg | INQUIRY |
Pyrophosphatase | CDSNT71 | 1 mL, 2 mL, 5 mL | INQUIRY | |
SM102 | CDSNT69 | 0.5 g, 1 g, 5 g | INQUIRY | |
Sucrose | CDSNT65 | 0.5 g, 1 g, 5 g | INQUIRY | |
T7 RNA polymerase | CDSNT73 | 1 mL, 2 mL, 5 mL | INQUIRY | |
UTP.3Na | CDSNT76 | 1 mL, 2 mL, 5 mL | INQUIRY |